BR112013005202A2 - entrega de drogas direcionadas a tumor baseadas em nanopartículas - Google Patents

entrega de drogas direcionadas a tumor baseadas em nanopartículas

Info

Publication number
BR112013005202A2
BR112013005202A2 BR112013005202A BR112013005202A BR112013005202A2 BR 112013005202 A2 BR112013005202 A2 BR 112013005202A2 BR 112013005202 A BR112013005202 A BR 112013005202A BR 112013005202 A BR112013005202 A BR 112013005202A BR 112013005202 A2 BR112013005202 A2 BR 112013005202A2
Authority
BR
Brazil
Prior art keywords
liposome
directed
lipid component
lipid
tumor
Prior art date
Application number
BR112013005202A
Other languages
English (en)
Other versions
BR112013005202B1 (pt
Inventor
Lu Dan
Liao Debbie
A Reisfeld Ralph
Xiang Rong
Chen Si
Chen Tingmei
Luo Yunping
Liu Ze
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BR112013005202A2 publication Critical patent/BR112013005202A2/pt
Publication of BR112013005202B1 publication Critical patent/BR112013005202B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

entrega de drogas direcionadas a tumor baseadas em nanopartículas. a presente invenção proporciona uma composição aquosa de nanopartículas de lipossoma direcionadas a um tumor que compreende uma dispersão aquosa de nanoparticulas de lipossomas. as nanopartículas encapsulam preferencialmente um agente quimioterapêutico anti-tumor, que pode ser adicionado a uma composição de lipossomas pré-formados ou podem ser incorporador nos lipossomas durante a formação dos lipossomas. as nanopartículas de lipossomas compreendem um lípidio direcionado a legumain em mistura com um ou mais outras micelas ou materiais formadores de vesículas lipídicas, na forma de nanopartículas de lipossomss dispersas num veículo aquoso. uma composção de nanopartícula lipossoma preferida direcionada a um tumor compreende (a) um componente lipídico direcionado a legumain, (b) um componente lípido zwitteriônico, (c) um componente lipídico amino-substituído, (d) um componente lípido neutro e (e) componente lipídico conjugado de polietilenoglicol. o componente lipídico direcionado a legumain que compreende uma porção hidrofóbica lipídica covalentemente ligada a uma porção de ligação ao legumain.
BR112013005202-3A 2010-09-02 2011-09-02 Lipídeo legumaína-alvo, composição de nanopartículas de legumaína-alvo e usos dos mesmos BR112013005202B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40268610P 2010-09-02 2010-09-02
US61/402,686 2010-09-02
US13/224,399 US9616137B2 (en) 2010-09-02 2011-09-02 Nanoparticle-based tumor-targeted drug delivery
PCT/US2011/050287 WO2012031175A2 (en) 2010-09-02 2011-09-02 Nanoparticle-based tumor-targeted drug delivery
US13/224,399 2011-09-02

Publications (2)

Publication Number Publication Date
BR112013005202A2 true BR112013005202A2 (pt) 2018-04-24
BR112013005202B1 BR112013005202B1 (pt) 2021-07-27

Family

ID=45770899

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013005202-3A BR112013005202B1 (pt) 2010-09-02 2011-09-02 Lipídeo legumaína-alvo, composição de nanopartículas de legumaína-alvo e usos dos mesmos

Country Status (16)

Country Link
US (3) US9616137B2 (pt)
EP (1) EP2611421B1 (pt)
JP (1) JP5871930B2 (pt)
KR (1) KR101817491B1 (pt)
CN (1) CN103179952B (pt)
AU (1) AU2011295792B2 (pt)
BR (1) BR112013005202B1 (pt)
CA (1) CA2809617C (pt)
ES (1) ES2694556T3 (pt)
IL (1) IL224940A (pt)
MX (1) MX2013002451A (pt)
NZ (1) NZ608748A (pt)
PT (1) PT2611421T (pt)
RU (1) RU2593367C2 (pt)
SG (1) SG188375A1 (pt)
WO (1) WO2012031175A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2825156T3 (en) 2012-03-16 2017-10-30 Merck Patent Gmbh TARGETED AMINO ACID LIPIDS
CN104398517A (zh) * 2014-11-28 2015-03-11 四川大学 乙胺嘧啶的新用途及治疗肿瘤的药物组合物
JP2017031079A (ja) * 2015-07-30 2017-02-09 国立大学法人鳥取大学 ポリヒスチジン修飾リポソーム
WO2017052255A1 (ko) * 2015-09-23 2017-03-30 세종대학교 산학협력단 탁산계 약물 전달용 리포좀 및 이의 제조방법
KR101685304B1 (ko) * 2015-10-02 2016-12-09 연세대학교 산학협력단 간 조직 특이적 유전자 발현 억제인자 전달용 나노리포좀
US10583083B1 (en) 2016-08-10 2020-03-10 Verily Life Sciences Llc ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
US10517823B1 (en) 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
US10835619B1 (en) 2016-08-19 2020-11-17 Verily Life Sciences Llc Targeted therapy to repolarize tumor-associated macrophages (TAMs)
US10751284B1 (en) 2016-08-19 2020-08-25 Verily Life Sciences Llc Targeted therapy to deplete tumor-associated macrophages (TAMs)
CN106924220A (zh) * 2017-04-29 2017-07-07 北京林业大学 一种肿瘤靶向多臂聚乙二醇‑雷公藤甲素纳米药物的制备
US11433143B2 (en) * 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
CN107823695B (zh) * 2017-09-19 2022-03-15 华东理工大学 一种智能型抗菌敷料及其制备方法
CN108434101A (zh) * 2018-04-08 2018-08-24 武汉迈德森医药科技股份有限公司 一种新型的用于抗癌的Tivozanib脂质体、制剂及其制备方法和应用
KR102087847B1 (ko) * 2018-04-19 2020-03-11 창원대학교 산학협력단 약물이 로딩된 인산염 미셀을 포함하는 약물전달체
EP3823668A1 (en) 2018-07-16 2021-05-26 DCPrime B.V. A combination product for use in tumor vaccination
CN108888773B (zh) * 2018-09-17 2021-06-29 中国医学科学院生物医学工程研究所 自组装球形药物纳米制剂及其制备方法与用途
JP7252582B2 (ja) * 2019-01-23 2023-04-05 アブティス・カンパニー・リミテッド 抗体－ペイロードコンジュゲートの調製のための化合物及びその使用
JP2022530044A (ja) 2019-04-25 2022-06-27 ディーシープライム・ベスローテン・フェンノートシャップ 腫瘍ワクチン接種方法
EP4127139A1 (en) 2020-03-27 2023-02-08 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN111481507B (zh) * 2020-04-10 2021-10-29 浙江大学 一种酶促阳离子化脂质体及其应用
CN114748424B (zh) * 2020-12-29 2024-01-30 中国科学院上海药物研究所 一种脂质体递药体系及其制备方法和用途
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN115105605B (zh) * 2021-03-17 2023-09-08 四川大学 一种主动靶向的抗肿瘤自组装纳米粒的制备及其应用
CN114306279A (zh) * 2021-12-30 2022-04-12 复旦大学 基于科罗索酸或其类似物的脂质纳米颗粒系统及其制备方法和应用
CN115089727B (zh) * 2022-06-08 2024-05-07 天津医科大学眼科医院 Kc26多肽修饰的牛奶外泌体及其制备方法和应用
CN118304404B (zh) * 2024-04-08 2024-09-17 海南大学 一种新型光诊疗的纳米制剂及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0843555B1 (en) * 1995-08-01 2003-08-27 Isis Pharmaceuticals, Inc. Liposomal oligonucleotide compositions
US6007839A (en) * 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US6339069B1 (en) * 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
EP1417220A2 (en) * 2001-08-13 2004-05-12 Probiodrug AG Irreversible cysteine protease inhibitors of legumain
US7056947B2 (en) 2002-07-05 2006-06-06 Georgia Tech Research Corp. Aza-peptide epoxides
EP1635858A4 (en) * 2003-05-29 2009-08-26 Scripps Research Inst TARGETED RELEASE ON CELLS EXPRESSING LEGUMINUM
EP1723124A1 (en) 2004-02-18 2006-11-22 Georgia Tech Research Corporation Propenoyl hydrazides
US20090220587A1 (en) * 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
WO2007064759A2 (en) * 2005-11-29 2007-06-07 The Scripps Research Institute Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain
WO2008079976A2 (en) * 2006-12-21 2008-07-03 Centocor, Inc. Dimeric high affinity egfr constructs and uses thereof
WO2011075678A1 (en) * 2009-12-18 2011-06-23 The Board Of Trustees Of The Leland Stanford Junior University Specific inhibitors and active site probes for legumain

Also Published As

Publication number Publication date
RU2013114474A (ru) 2014-10-10
US20130330399A1 (en) 2013-12-12
BR112013005202B1 (pt) 2021-07-27
WO2012031175A3 (en) 2012-06-14
CN103179952A (zh) 2013-06-26
US10335420B2 (en) 2019-07-02
JP5871930B2 (ja) 2016-03-01
US20120058177A1 (en) 2012-03-08
AU2011295792A1 (en) 2013-04-18
KR20140017486A (ko) 2014-02-11
CN103179952B (zh) 2015-06-03
SG188375A1 (en) 2013-04-30
CA2809617C (en) 2020-04-21
WO2012031175A4 (en) 2012-08-09
EP2611421A2 (en) 2013-07-10
WO2012031175A8 (en) 2012-10-18
WO2012031175A9 (en) 2012-09-20
PT2611421T (pt) 2018-11-22
MX2013002451A (es) 2013-05-01
ES2694556T3 (es) 2018-12-21
JP2013536867A (ja) 2013-09-26
US9629922B2 (en) 2017-04-25
EP2611421B1 (en) 2018-10-24
RU2593367C2 (ru) 2016-08-10
IL224940A (en) 2017-06-29
US9616137B2 (en) 2017-04-11
WO2012031175A2 (en) 2012-03-08
NZ608748A (en) 2015-05-29
AU2011295792B2 (en) 2015-09-03
CA2809617A1 (en) 2012-03-08
KR101817491B1 (ko) 2018-01-11
US20170224838A1 (en) 2017-08-10
EP2611421A4 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
BR112013005202A2 (pt) entrega de drogas direcionadas a tumor baseadas em nanopartículas
Gao et al. Neuronal mitochondria-targeted delivery of curcumin by biomimetic engineered nanosystems in Alzheimer's disease mice
Cheng et al. TPGS‐functionalized polydopamine‐modified mesoporous silica as drug nanocarriers for enhanced lung cancer chemotherapy against multidrug resistance
Bruni et al. Nanostructured delivery systems with improved leishmanicidal activity: a critical review
Zhu et al. Co-delivery of vincristine and quercetin by nanocarriers for lymphoma combination chemotherapy
Sesarman et al. Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment
Savla et al. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer
EP2861256B1 (en) Compositions for treating cancer and methods for making the same
Zhao et al. Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatform: A dual cell therapy to regress plaques
Choukaife et al. Current advances in chitosan nanoparticles based oral drug delivery for colorectal cancer treatment
Kim et al. Targeted delivery of EV peptide to tumor cell cytoplasm using lipid coated calcium carbonate nanoparticles
Wolfram et al. Hesperetin liposomes for cancer therapy
Rui et al. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells
Cui et al. pH-triggered charge-reversal mesoporous silica nanoparticles stabilized by chitosan oligosaccharide/carboxymethyl chitosan hybrids for effective intracellular delivery of doxorubicin
WO2011153493A3 (en) Biodegradable lipids for the delivery of active agents
Shigehiro et al. Efficient drug delivery of paclitaxel glycoside: A novel solubility gradient encapsulation into liposomes coupled with immunoliposomes preparation
Sakpakdeejaroen et al. Transferrin‐bearing liposomes entrapping plumbagin for targeted cancer therapy
Hou et al. Multifunctional hyaluronic acid modified graphene oxide loaded with mitoxantrone for overcoming drug resistance in cancer
Yang et al. Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy
WO2012095543A1 (es) Nanocápsulas con cubierta polimérica
Ma et al. Cancer cell targeting, controlled drug release and intracellular fate of biomimetic membrane-encapsulated drug-loaded nano-graphene oxide nanohybrids
CN105434437B (zh) 一种奥沙利铂和伊立替康类药物共载脂质体及其制备方法
Karim et al. Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol
Thapa et al. Hydrophobic binding peptide-conjugated hybrid lipid-mesoporous silica nanoparticles for effective chemo-photothermal therapy of pancreatic cancer
Liu et al. Intelligent delivery system targeting PD-1/PD-L1 pathway for cancer immunotherapy

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/09/2011, OBSERVADAS AS CONDICOES LEGAIS.